ReviewDiagnostics (Basel, Switzerland)2020
Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Effects of co-administered melatonin and methylphenidate on cognitive impairment and histopathological alterations in an AlCl₃-induced neurotoxicity model of alzheimer's disease in BALB/C mice.Scientific reports · 2026Article
- Preparation of Dual-Network Hydrogels and Their Application in Flexible Electronics.Gels (Basel, Switzerland) · 2025Review
- Article
- AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring.Biosensors · 2024Review
- Natural flavonoids as potential therapeutics in the management of Alzheimer's disease: a review.3 Biotech · 2024Review
- Using cerebrospinal fluid biomarkers to diagnose Alzheimer's disease: an Australian perspective.Frontiers in psychiatry · 2024Article
- Alzheimer's Disease: Significant Benefit from the Yeast-Based Models.International journal of molecular sciences · 2023Review
- Altered Mitochondrial Morphology and Bioenergetics in a New Yeast Model Expressing Aβ42.International journal of molecular sciences · 2023Article
- Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.Journal of Alzheimer's disease : JAD · 2023Article
- Combination of Serum and Plasma Biomarkers Could Improve Prediction Performance for Alzheimer's Disease.Genes · 2022Article
- Effects of Electroacupuncture on the Correlation between Serum and Central Immunity in AD Model Animals.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- New RNA-Based Breakthroughs in Alzheimer's Disease Diagnosis and Therapeutics.Pharmaceutics · 2021Review
- News about the Role of Fluid and Imaging Biomarkers in Neurodegenerative Diseases.Biomedicines · 2021Review
- Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.Advances in experimental medicine and biology · 2021Review
- The Viral Hypothesis in Alzheimer's Disease: Novel Insights and Pathogen-Based Biomarkers.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a complex neurodegenerative disease that requires extremely specific biomarkers for its diagnosis. For current diagnostics capable of identifying AD, the development and validation of early stage biomarkers is a top research priority. Body-fluid biomarkers might closely reflect synaptic dysfunction in the brain and, thereby, could contribute to improving diagnostic accuracy and monitoring disease progression, and serve as markers for assessing the response to disease-modifying therapies at early onset. Here, we highlight current advances in the research on the capabilities of body-fluid biomarkers and their role in AD pathology. Then, we describe and discuss current applications of the potential biomarkers in clinical diagnostics in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.